Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VNN1 | O95497 | 5/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.44 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
| ▸ | CTSA | P10619 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4914995 | 0.81 | NPSR1 (0.39) | VNN1CTSASMN1; SMN2KDM4ESCN9A | |
| SCHEMBL4915001 | 0.81 | NPSR1 (0.39) | VNN1CTSASMN1; SMN2KDM4ESCN9A | |
| SCHEMBL27248000 | 0.77 | ALDH1A1 (0.44) | NPC1CTSASMN1; SMN2KDM4ESCN9A | |
| SCHEMBL31599570 | 0.77 | ALDH1A1 (0.44) | NPC1CTSASMN1; SMN2KDM4ESCN9A | |
| SCHEMBL31459066 | 0.77 | TPMT (0.49) | CTSAKDM4EALDH1A1 | |
| SCHEMBL1425009 | 0.77 | TPMT (0.49) | CTSAKDM4EALDH1A1 | |
| SCHEMBL1425265 | 0.75 | MAPK1 (0.46) | NPC1SMN1; SMN2KDM4EALDH1A1LMNA | |
| SCHEMBL4927538 | 0.74 | NNMT (0.60) | VNN1RXFP1NPC1PDE10ALTA4H | |
| SCHEMBL25981388 | 0.73 | NPC1 (0.59) | VNN1RXFP1NPC1LTA4HSMN1; SMN2 | |
| SCHEMBL26168167 | 0.72 | CYP2C9 (0.41) | SMN1; SMN2SCN9ALMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080306055-A1 | Heterocyclic Mchr1 Antagonists And Their Use In Therapy | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | US | disclosed |
| EP-1831194-A1 | HETEROCYCLIC MCHr1 ANTAGONISTS AND THEIR USE IN THERAPY | AstraZeneca AB (SE) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006068594-A1 | HETEROCYCLIC MCHr1 ANTAGONISTS AND THEIR USE IN THERAPY | ASTRAZENECA AB (SE) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306055-A1 | Heterocyclic Mchr1 Antagonists And Their Use In Therapy | MCHR1, MCHR2, MC1R | VNN1 4382/4885RXFP1 301/4885NPC1 381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.